| Year |
Citation |
Score |
| 2024 |
Rosenbaum SR, Hughes CJ, Fields KM, Purdy SC, Gustafson A, Wolin A, Hampton D, Turner N, Ebmeier C, Costello JC, Ford HL. An EYA3/NF-κB/CCL2 signaling axis suppresses cytotoxic NK cells in the pre-metastatic niche to promote triple negative breast cancer metastasis. Biorxiv : the Preprint Server For Biology. PMID 39211066 DOI: 10.1101/2024.07.31.606072 |
0.464 |
|
| 2024 |
Gardner L, Rossi J, Armstrong B, Muse M, LaVeck A, Blevins M, Zhang L, Ford H, Zhao R, Wang X. Rational design of novel allosteric EYA2 inhibitors as potential therapeutics for multiple brain cancers. Chemmedchem. e202400179. PMID 38861151 DOI: 10.1002/cmdc.202400179 |
0.368 |
|
| 2024 |
Hughes CJ, Alderman C, Wolin AR, Fields KM, Zhao R, Ford HL. All eyes on Eya: A unique transcriptional co-activator and phosphatase in cancer. Biochimica Et Biophysica Acta. Reviews On Cancer. 1879: 189098. PMID 38555001 DOI: 10.1016/j.bbcan.2024.189098 |
0.388 |
|
| 2023 |
Souto EP, Gong P, Landua JD, Srinivasan RR, Ganesan A, Dobrolecki LE, Purdy SC, Ford HL, Lewis MT. Interferon-Induced Bone Marrow Stromal Antigen 2 (BST2) Is A Functional Tumor-Initiating Cell Marker In Triple-Negative Breast Cancer. Biorxiv : the Preprint Server For Biology. PMID 37745510 DOI: 10.1101/2023.09.15.557958 |
0.44 |
|
| 2023 |
Hughes CJ, Fields KM, Danis EP, Hsu JY, Neelakantan D, Vincent MY, Gustafson AL, Oliphant MJ, Sreekanth V, Zaberezhnyy V, Costello JC, Jedlicka P, Ford HL. SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma. Nature Communications. 14: 4357. PMID 37468459 DOI: 10.1038/s41467-023-39945-w |
0.364 |
|
| 2021 |
Zhang G, Dong Z, Gimple RC, Wolin A, Wu Q, Qiu Z, Wood LM, Shen JZ, Jiang L, Zhao L, Lv D, Prager BC, Kim LJY, Wang X, Zhang L, ... ... Ford HL, et al. Targeting EYA2 tyrosine phosphatase activity in glioblastoma stem cells induces mitotic catastrophe. The Journal of Experimental Medicine. 218. PMID 34617969 DOI: 10.1084/jem.20202669 |
0.318 |
|
| 2020 |
Kong D, Zhou H, Neelakantan D, Hughes CJ, Hsu JY, Srinivasan RR, Lewis MT, Ford HL. VEGF-C mediates tumor growth and metastasis through promoting EMT-epithelial breast cancer cell crosstalk. Oncogene. PMID 33299122 DOI: 10.1038/s41388-020-01539-x |
0.508 |
|
| 2020 |
Zhou H, Zhang L, Vartuli RL, Ford HL, Zhao R. Corrigendum to "The Eya phosphatase: Its unique role in cancer" [Int. J. Biochem. Cell Biol. 96 (2018) 165-170]. The International Journal of Biochemistry & Cell Biology. 105847. PMID 32933829 DOI: 10.1016/J.Biocel.2020.105847 |
0.456 |
|
| 2020 |
Kong D, Hughes CJ, Ford HL. Cellular Plasticity in Breast Cancer Progression and Therapy. Frontiers in Molecular Biosciences. 7: 72. PMID 32391382 DOI: 10.3389/Fmolb.2020.00072 |
0.55 |
|
| 2020 |
Zhou H, Blevins MA, Hsu JY, Kong D, Galbraith MD, Goodspeed A, Culp-Hill R, Oliphant MU, Ramirez D, Zhang L, Pineiro JT, Mathews Griner L, King R, Barnaeva E, Hu X, ... ... Ford HL, et al. A SIX1/EYA2 small molecule inhibitor disrupts EMT and metastasis. Cancer Research. PMID 32341035 DOI: 10.1158/0008-5472.Can-20-0435 |
0.598 |
|
| 2020 |
Oliphant MUJ, Kong D, Zhou H, Lewis MT, Ford HL. Two Sides of the Same Coin: The Role of Developmental pathways and pluripotency factors in normal mammary stem cells and breast cancer metastasis. Journal of Mammary Gland Biology and Neoplasia. PMID 32323111 DOI: 10.1007/S10911-020-09449-0 |
0.573 |
|
| 2020 |
Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Campbell K, Cano A, Casanova J, Christofori G, Dedhar S, Derynck R, Ford HL, Fuxe J, García de Herreros A, et al. Guidelines and definitions for research on epithelial-mesenchymal transition. Nature Reviews. Molecular Cell Biology. PMID 32300252 DOI: 10.1038/S41580-020-0237-9 |
0.353 |
|
| 2020 |
Zhou H, Blevins M, Kong D, Hsu J, Galbraith M, Goodspeed A, Culp-Hill R, Oliphant M, Ramirez D, Gustafson D, D'Alessandro A, Costello J, Patnaik S, Marugan J, Zhao R, ... Ford H, et al. Novel Small Molecule Compound disrupts the SIX1/EYA2 Complex and Inhibits Breast Cancer Metastasis The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.02458 |
0.463 |
|
| 2020 |
Ford HL, Kong D, Neelakantan D, Zhou H, Hughes C, Lewis M, Marugan J, Patnaik S, Zhao R. Developing Novel Means to Inhibit Metastasis Through Targeting Tumor Heterogeneity and EMT The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.00374 |
0.416 |
|
| 2019 |
Anantharajan J, Zhou H, Zhang L, Hotz T, Vincent MY, Blevins MA, Jansson AE, Liang Kuan JW, Ng EY, Yeo K, Baburajendran N, Lin G, Hung AW, Joy J, Patnaik S, ... ... Ford HL, et al. Structural and functional analyses of an allosteric Eya2 phosphatase inhibitor that has on target effects in human lung cancer cells. Molecular Cancer Therapeutics. PMID 31285279 DOI: 10.1158/1535-7163.Mct-18-1239 |
0.462 |
|
| 2019 |
Oliphant MUJ, Vincent MY, Galbraith MD, Pandey A, Zaberezhnyy V, Rudra P, Johnson KR, Costello JC, Ghosh D, DeGregori J, Espinosa JM, Ford HL. Six2 mediates late-stage metastasis via direct regulation of Sox2 and induction of a cancer stem cell program. Cancer Research. PMID 30606720 DOI: 10.1158/0008-5472.Can-18-1791 |
0.544 |
|
| 2019 |
Ford H. Abstract ES2-1: The EMT and metastasis controversy: Where things stand in 2018 Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Es2-1 |
0.521 |
|
| 2019 |
Kong D, Neelakantan D, Zhou H, Lewis MT, Ford HL. Abstract 5152: EMT cells increase the metastatic potential of neighboring carcinoma cells via non-canonical activation of GLI signaling through secretion of VEGF-C Cancer Research. 79: 5152-5152. DOI: 10.1158/1538-7445.Sabcs18-5152 |
0.555 |
|
| 2018 |
Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL. Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nature Communications. 9: 4720. PMID 30420638 DOI: 10.1038/S41467-018-07168-Z |
0.375 |
|
| 2018 |
Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL. Author Correction: Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nature Communications. 9: 3830. PMID 30224630 DOI: 10.1038/S41467-018-06265-3 |
0.512 |
|
| 2018 |
Vartuli RL, Zhou H, Zhang L, Powers RK, Klarquist J, Rudra P, Vincent MY, Ghosh D, Costello JC, Kedl RM, Slansky JE, Zhao R, Ford HL. Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. The Journal of Clinical Investigation. PMID 29757193 DOI: 10.1172/Jci96784 |
0.477 |
|
| 2018 |
Guarnieri AL, Towers CG, Drasin DJ, Oliphant MUJ, Andrysik Z, Hotz TJ, Vartuli RL, Linklater ES, Pandey A, Khanal S, Espinosa JM, Ford HL. The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene. PMID 29662198 DOI: 10.1038/S41388-018-0239-7 |
0.55 |
|
| 2018 |
Zhang L, Zhou H, Li X, Vartuli RL, Rowse M, Xing Y, Rudra P, Ghosh D, Zhao R, Ford HL. Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. Nature Communications. 9: 1047. PMID 29535359 DOI: 10.1038/S41467-018-03327-4 |
0.445 |
|
| 2018 |
Oliphant MU, Pandey A, Johnson K, Powers R, Galbraith M, Costello J, Ford HL. Abstract 5001: Identification of a Six2/Sox2/Nanog stem cell axis that promotes breast cancer metastatic colonization Cancer Research. 78: 5001-5001. DOI: 10.1158/1538-7445.Am2018-5001 |
0.588 |
|
| 2017 |
Zhou H, Zhang L, Vartuli RL, Ford HL, Zhao R. The Eya phosphatase: Its unique role in cancer. The International Journal of Biochemistry & Cell Biology. PMID 28887153 DOI: 10.1016/J.Biocel.2017.09.001 |
0.48 |
|
| 2017 |
Neelakantan D, Zhou H, Oliphant MUJ, Zhang X, Simon LM, Henke DM, Shaw CA, Wu MF, Hilsenbeck SG, White LD, Lewis MT, Ford HL. EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nature Communications. 8: 15773. PMID 28604738 DOI: 10.1038/Ncomms15773 |
0.528 |
|
| 2017 |
Tavares ALP, Cox TC, Maxson RM, Ford HL, Clouthier DE. Negative regulation of Endothelin signaling by SIX1 is required for proper maxillary development. Development (Cambridge, England). PMID 28455376 DOI: 10.1242/Dev.145144 |
0.331 |
|
| 2017 |
Dimberg L, Towers CG, Behbakht K, Hotz T, Kim J, Fosmire SP, Porter CC, Tan AC, Thorburn A, Ford HL. A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Molecular Cancer Research : McR. PMID 28108622 DOI: 10.1158/1541-7786.Mcr-16-0234 |
0.407 |
|
| 2017 |
Thorburn J, Staskiewicz L, Goodall ML, Dimberg L, Frankel AE, Ford HL, Thorburn A. Non-cell-autonomous Effects of Autophagy Inhibition in Tumor Cells Promote Growth of Drug-resistant Cells. Molecular Pharmacology. 91: 58-64. PMID 27974637 DOI: 10.1124/Mol.116.106070 |
0.421 |
|
| 2016 |
Kendrick AA, Schafer J, Dzieciatkowska M, Nemkov T, Alessandro AD, Neelakantan D, Ford HL, Pearson CG, Weekes CD, Hansen KC, Eisenmesser EZ. CD147: a small molecule transporter ancillary protein at the crossroad of multiple hallmarks of cancer and metabolic reprogramming. Oncotarget. PMID 28039486 DOI: 10.18632/Oncotarget.14272 |
0.33 |
|
| 2016 |
Zhou H, Neelakantan D, Ford HL. Clonal cooperativity in heterogenous cancers. Seminars in Cell & Developmental Biology. PMID 27582427 DOI: 10.1016/J.Semcdb.2016.08.028 |
0.458 |
|
| 2016 |
Kohrt D, Hinds P, Ford H, Grossel M. Abstract A38: In vitro and in vivo interaction of Cdk6 and Eya2 indicate potential crosstalk Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Devbiolca15-A38 |
0.373 |
|
| 2016 |
Neelakantan D, Zhou H, Cabrera J, Ford H. Abstract B46: EMT-inducing transcription factors Twist1, Snail1 and Six1 increase metastasis of neighboring tumor cells via induction of Hedgehog-Gli signaling Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-B46 |
0.574 |
|
| 2016 |
Zhou H, Neelakantan D, Ford HL. Abstract 1586: Breast cancer cells overexpressing EMT-inducing transcription factors mediate metastasis of neighboring tumor cells via secretion of molecules that upregulate Hedgehog signaling Cancer Research. 76: 1586-1586. DOI: 10.1158/1538-7445.Am2016-1586 |
0.584 |
|
| 2015 |
Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, ... Ford HL, et al. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nature Communications. 6: 10077. PMID 26687066 DOI: 10.1038/Ncomms10077 |
0.76 |
|
| 2015 |
Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan AC, Ford HL. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Research. 75: 1908-21. PMID 25716682 DOI: 10.1158/0008-5472.Can-14-2394 |
0.621 |
|
| 2015 |
Blevins MA, Towers CG, Patrick AN, Zhao R, Ford HL. The SIX1-EYA transcriptional complex as a therapeutic target in cancer. Expert Opinion On Therapeutic Targets. 19: 213-25. PMID 25555392 DOI: 10.1517/14728222.2014.978860 |
0.745 |
|
| 2014 |
Neelakantan D, Drasin DJ, Ford HL. Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis. Cell Adhesion & Migration. 1-12. PMID 25482627 DOI: 10.4161/19336918.2014.972761 |
0.447 |
|
| 2014 |
Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. Breast Cancer Research : Bcr. 16: 462. PMID 25358638 DOI: 10.1186/S13058-014-0462-2 |
0.64 |
|
| 2014 |
Wang CA, Drasin D, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello JC, Tan AC, Ford HL. Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. Cancer Research. 74: 7357-70. PMID 25348955 DOI: 10.1158/0008-5472.Can-14-0666 |
0.697 |
|
| 2014 |
Krueger AB, Drasin DJ, Lea WA, Patrick AN, Patnaik S, Backos DS, Matheson CJ, Hu X, Barnaeva E, Holliday MJ, Blevins MA, Robin TP, Eisenmesser EZ, Ferrer M, Simeonov A, ... ... Ford HL, et al. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration. The Journal of Biological Chemistry. 289: 16349-61. PMID 24755226 DOI: 10.1074/Jbc.M114.566729 |
0.777 |
|
| 2014 |
O'Brien JH, Hernandez-Lagunas L, Artinger KB, Ford HL. MicroRNA-30a regulates zebrafish myogenesis through targeting the transcription factor Six1. Journal of Cell Science. 127: 2291-301. PMID 24634509 DOI: 10.1242/Jcs.143677 |
0.426 |
|
| 2014 |
Kohrt D, Crary J, Zimmer M, Patrick AN, Ford HL, Hinds PW, Grossel MJ. CDK6 binds and promotes the degradation of the EYA2 protein. Cell Cycle (Georgetown, Tex.). 13: 62-71. PMID 24196439 DOI: 10.4161/Cc.26755 |
0.654 |
|
| 2014 |
Powell DR, O'Brien JH, Ford HL, Artinger KB. Neural Crest Cells and Cancer. Insights into Tumor Progression. Neural Crest Cells: Evolution, Development and Disease. 335-357. DOI: 10.1016/B978-0-12-401730-6.00017-X |
0.374 |
|
| 2013 |
Cieply B, Farris J, Denvir J, Ford HL, Frisch SM. Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Research. 73: 6299-309. PMID 23943797 DOI: 10.1158/0008-5472.Can-12-4082 |
0.565 |
|
| 2013 |
Auvergne RM, Sim FJ, Wang S, Chandler-Militello D, Burch J, Al Fanek Y, Davis D, Benraiss A, Walter K, Achanta P, Johnson M, Quinones-Hinojosa A, Natesan S, Ford HL, Goldman SA. Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Reports. 3: 2127-41. PMID 23727239 DOI: 10.1016/J.Celrep.2013.04.035 |
0.393 |
|
| 2013 |
Patrick AN, Cabrera JH, Smith AL, Chen XS, Ford HL, Zhao R. Structure-function analyses of the human SIX1-EYA2 complex reveal insights into metastasis and BOR syndrome. Nature Structural & Molecular Biology. 20: 447-53. PMID 23435380 DOI: 10.1038/Nsmb.2505 |
0.662 |
|
| 2013 |
Krueger AB, Dehdashti SJ, Southall N, Marugan JJ, Ferrer M, Li X, Ford HL, Zheng W, Zhao R. Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity. Journal of Biomolecular Screening. 18: 85-96. PMID 22820394 DOI: 10.1177/1087057112453936 |
0.449 |
|
| 2013 |
Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene. 32: 1341-50. PMID 22580613 DOI: 10.1038/Onc.2012.164 |
0.355 |
|
| 2013 |
Wang C, Jedlicka P, Tan A, Pham C, Zaberezhnvv V, Ford H. Abstract PR04: The Six2 homeoprotein mediates breast cancer metastasis via repressing E-cadherin Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-Pr04 |
0.732 |
|
| 2013 |
Neelakantan D, Iwanaga R, Drasin DJ, Ford HL. Abstract B084: EMT-inducing transcription factors Twist1 and Snail1 non-cell autonomously increase metastatic properties of non-Twist1 or Snail1 expressing cells via induction of Six1 Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B084 |
0.546 |
|
| 2013 |
Kohrt D, Crary J, Zimmer M, Ford H, Hinds P, Grossel M. Abstract A18: CDK6 binds and promotes the degradation of the EYA2 protein Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-A18 |
0.45 |
|
| 2013 |
Cieply B, Ford HL, Farris J, Frisch S. Abstract A15: A reciprocal feedback loop between grainyhead-like-2 and ZEB1 controls EMT and tumor suppression Cancer Research. 73. DOI: 10.1158/1538-7445.Fbcr13-A15 |
0.568 |
|
| 2013 |
Garlington CN, Micalizzi DS, Ford HL. Abstract 782: The Six1 homeoprotein downregulates p53, via a novel, MDM2 independent mechanism. Cancer Research. 73: 782-782. DOI: 10.1158/1538-7445.Am2013-782 |
0.44 |
|
| 2013 |
Wang C, Jedlicka P, Zaberezhnyy V, Tan A, Ford H. Abstract 2705: Novel functions of the homeoprotein SIX2 in mediating anchorage independence and metastasis in breast cancer. Cancer Research. 73: 2705-2705. DOI: 10.1158/1538-7445.Am2013-2705 |
0.601 |
|
| 2013 |
Dimberg LY, Cabrera J, Menke C, Kim J, Porter CC, Tan A, Behbakht K, Thorburn A, Ford HL. Abstract B115: Use of a genome-wide loss-of-function screen to identify novel mechanisms of resistance to TRAIL induced apoptosis. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B115 |
0.44 |
|
| 2013 |
Patrick A, Blevins M, Krueger A, Cabrera J, Backos D, Reigan P, Zhao R, Ford H. Abstract B102: Targeting the SIX1/EYA transcriptional complex as a potential anti-cancer therapy. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B102 |
0.702 |
|
| 2013 |
Wang C, Iwanaga R, Ford H. Abstract A58: Targeting vascular growth factor C (VEGF-C) in cancer stem-like populations sensitizes cells to oxidative stress and inhibits tumor progression via regulation of superoxide dismutase 3 (Sod3) in a mouse model of breast cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A58 |
0.507 |
|
| 2012 |
Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Research : Bcr. 14: R100. PMID 22765220 DOI: 10.1186/Bcr3219 |
0.823 |
|
| 2012 |
Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P, Ford HL. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Molecular Cancer Research : McR. 10: 1098-108. PMID 22723308 DOI: 10.1158/1541-7786.Mcr-12-0086 |
0.714 |
|
| 2012 |
Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4514-21. PMID 22711703 DOI: 10.1158/1078-0432.Ccr-11-3224 |
0.736 |
|
| 2012 |
Wang CA, Jedlicka P, Patrick AN, Micalizzi DS, Lemmer KC, Deitsch E, Casás-Selves M, Harrell JC, Ford HL. SIX1 induces lymphangiogenesis and metastasis via upregulation of VEGF-C in mouse models of breast cancer. The Journal of Clinical Investigation. 122: 1895-906. PMID 22466647 DOI: 10.1172/Jci59858 |
0.822 |
|
| 2012 |
Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecologic Oncology. 125: 451-7. PMID 22333994 DOI: 10.1016/J.Ygyno.2012.02.007 |
0.669 |
|
| 2012 |
Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Tan AC, Ford HL. The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene. 31: 5162-71. PMID 22286770 DOI: 10.1038/Onc.2012.11 |
0.751 |
|
| 2012 |
Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-β signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene. 31: 552-62. PMID 21706047 DOI: 10.1038/Onc.2011.259 |
0.841 |
|
| 2012 |
Smith AL, Iwanaga R, Drasin DJ, Micalizzi DS, Vartuli RL, Ford HL. Abstract A20: The Six1-regulated miR-106b-25 cluster is a mediator of the tumor promotional effects of TGF- signaling in human breast cancer Cancer Research. 72: A20-A20. DOI: 10.1158/1538-7445.Nonrna12-A20 |
0.748 |
|
| 2012 |
Smith A, Iwanaga R, Drasin D, Micalizzi D, Vartuli R, Ford H. 411 The miR-106b-25 Cluster as a Potential Target for Six1-mediated Breast Cancer Metastasis, and a Molecular Marker of the TGFβ Paradox European Journal of Cancer. 48: 125. DOI: 10.1016/S0959-8049(12)72209-8 |
0.361 |
|
| 2011 |
Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Research : Bcr. 13: 226. PMID 22078097 DOI: 10.1186/Bcr3037 |
0.772 |
|
| 2011 |
Menke C, Bin L, Thorburn J, Behbakht K, Ford HL, Thorburn A. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents. Cancer Research. 71: 1883-92. PMID 21363923 DOI: 10.1158/0008-5472.Can-10-2252 |
0.331 |
|
| 2011 |
Menke C, Goncharov T, Qamar L, Korch C, Ford HL, Behbakht K, Thorburn A. TRAIL receptor signaling regulation of chemosensitivity in vivo but not in vitro. Plos One. 6: e14527. PMID 21264287 DOI: 10.1371/Journal.Pone.0014527 |
0.414 |
|
| 2011 |
Ford H, Patrick A, Varella-Garcia M. SIX1 (sine oculis homeobox homolog 1) (mammalian) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/38295 |
0.56 |
|
| 2011 |
Robin T, Reaves L, Mckinsey E, Jedlicka P, Ford H. Abstract 5337: The role of Eya3 as a target of EWS/Fli1 in Ewing's sarcoma Cancer Research. 71: 5337-5337. DOI: 10.1158/1538-7445.Am2011-5337 |
0.619 |
|
| 2011 |
Wang C, Jedlicka P, Christensen KL, Micalizzi DS, Harrell JC, Ford HL. Abstract 1463: SIX1 induces lymphatic and distant metastasis by upregulating VEGF-C and stimulating lymphangiogenesis in breast cancer Cancer Research. 71: 1463-1463. DOI: 10.1158/1538-7445.Am2011-1463 |
0.801 |
|
| 2011 |
Krueger A, Dehdashti S, Southhall N, Patnaik S, Marugan J, Zheng W, Ford H, Zhao R. Abstract 1378: Identification and characterization of small molecule inhibitors targeting Eya phosphatase activity for anti-breast cancer therapy Cancer Research. 71: 1378-1378. DOI: 10.1158/1538-7445.Am2011-1378 |
0.566 |
|
| 2011 |
Blevins M, An J, Jones S, Swaroop M, Ferrer M, Ford H, Zhao R. Abstract 1373: Identification of potential anti-tumor therapeutics targeting the Six1 transcriptional complex Cancer Research. 71: 1373-1373. DOI: 10.1158/1538-7445.Am2011-1373 |
0.574 |
|
| 2011 |
Yang Y, Weng J, Welsh M, Ford HL, Lonning SM, Wakefield L. Abstract 1090: Development of predictive biomarkers for anti-TGF-beta therapy Cancer Research. 71: 1090-1090. DOI: 10.1158/1538-7445.Am2011-1090 |
0.439 |
|
| 2011 |
Patrick A, Cabrera J, Zhao R, Ford H. Abstract C127: Crystal structure of the SIX1/EYA transcriptional complex reveals ways to inhibit SIX1-mediated breast tumorigenesis/metastasis. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C127 |
0.72 |
|
| 2011 |
Robin TP, Kreuger A, McKinsey E, Reaves L, Jedlicka P, Zhao R, Ford HL. Abstract B78: A novel EWS/Fli1 target gene, Eya3, is upregulated in Ewing's sarcoma to mediate chemoresistance. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B78 |
0.709 |
|
| 2010 |
Micalizzi DS, Wang CA, Farabaugh SM, Schiemann WP, Ford HL. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Research. 70: 10371-80. PMID 21056993 DOI: 10.1158/0008-5472.Can-10-1354 |
0.803 |
|
| 2010 |
Ford HL, Thompson EW. Mammary gland studies as important contributors to the cause of epithelial mesenchymal plasticity in malignancy. Journal of Mammary Gland Biology and Neoplasia. 15: 113-5. PMID 20544376 DOI: 10.1007/S10911-010-9182-0 |
0.525 |
|
| 2010 |
Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. Journal of Mammary Gland Biology and Neoplasia. 15: 117-34. PMID 20490631 DOI: 10.1007/S10911-010-9178-9 |
0.832 |
|
| 2010 |
Coletta RD, McCoy EL, Burns V, Kawakami K, McManaman JL, Wysolmerski JJ, Ford HL. Characterization of the Six1 homeobox gene in normal mammary gland morphogenesis. Bmc Developmental Biology. 10: 4. PMID 20074369 DOI: 10.1186/1471-213X-10-4 |
0.742 |
|
| 2010 |
Menke CR, Bin L, Thorburn J, Behbakht K, Ford H, Thorburn A. Abstract 207: Distinct TRAIL resistance mechanisms can be overcome by proteosome inhibition Cancer Research. 70: 207-207. DOI: 10.1158/1538-7445.Am10-207 |
0.363 |
|
| 2009 |
Micalizzi DS, Ford HL. Epithelial-mesenchymal transition in development and cancer. Future Oncology (London, England). 5: 1129-43. PMID 19852726 DOI: 10.2217/Fon.09.94 |
0.791 |
|
| 2009 |
Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. The Journal of Clinical Investigation. 119: 2678-90. PMID 19726885 DOI: 10.1172/Jci37815 |
0.79 |
|
| 2009 |
McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. The Journal of Clinical Investigation. 119: 2663-77. PMID 19726883 DOI: 10.1172/Jci37691 |
0.758 |
|
| 2009 |
Patrick AN, Schiemann BJ, Yang K, Zhao R, Ford HL. Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutations. The Journal of Biological Chemistry. 284: 20781-90. PMID 19497856 DOI: 10.1074/Jbc.M109.016832 |
0.575 |
|
| 2009 |
McCoy EL, Kawakami K, Ford HL, Coletta RD. Expression of Six1 homeobox gene during development of the mouse submandibular salivary gland. Oral Diseases. 15: 407-13. PMID 19371398 DOI: 10.1111/J.1601-0825.2009.01560.X |
0.703 |
|
| 2009 |
Farabaugh SM, Welm AL, Ford HL. Abstract A40: Six1 is dependent on its coactivator Eya2 to mediate tumor progression in the MCF7 mammary carcinoma cell line Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-A40 |
0.813 |
|
| 2008 |
Christensen KL, Patrick AN, McCoy EL, Ford HL. The six family of homeobox genes in development and cancer. Advances in Cancer Research. 101: 93-126. PMID 19055944 DOI: 10.1016/S0065-230X(08)00405-3 |
0.776 |
|
| 2008 |
Coletta RD, Christensen KL, Micalizzi DS, Jedlicka P, Varella-Garcia M, Ford HL. Six1 overexpression in mammary cells induces genomic instability and is sufficient for malignant transformation. Cancer Research. 68: 2204-13. PMID 18381426 DOI: 10.1158/0008-5472.Can-07-3141 |
0.778 |
|
| 2008 |
Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 11: 17-24. PMID 18374623 DOI: 10.1016/J.Drup.2008.02.001 |
0.351 |
|
| 2007 |
Behbakht K, Qamar L, Aldridge CS, Coletta RD, Davidson SA, Thorburn A, Ford HL. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Research. 67: 3036-42. PMID 17409410 DOI: 10.1158/0008-5472.Can-06-3755 |
0.39 |
|
| 2007 |
Christensen KL, Brennan JDG, Aldridge CS, Ford HL. Cell cycle regulation of the human Six1 homeoprotein is mediated by APCCdh1 Oncogene. 26: 3406-3414. PMID 17130831 DOI: 10.1038/Sj.Onc.1210122 |
0.422 |
|
| 2005 |
Reichenberger KJ, Coletta RD, Schulte AP, Varella-Garcia M, Ford HL. Gene amplification is a mechanism of Six1 overexpression in breast cancer. Cancer Research. 65: 2668-75. PMID 15805264 DOI: 10.1158/0008-5472.Can-04-4286 |
0.556 |
|
| 2004 |
Coletta RD, Christensen K, Reichenberger KJ, Lamb J, Micomonaco D, Huang L, Wolf DM, Müller-Tidow C, Golub TR, Kawakami K, Ford HL. The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1. Proceedings of the National Academy of Sciences of the United States of America. 101: 6478-83. PMID 15123840 DOI: 10.1073/Pnas.0401139101 |
0.454 |
|
| 2004 |
Coletta RD, Jedlicka P, Gutierrez-Hartmann A, Ford HL. Transcriptional control of the cell cycle in mammary gland development and tumorigenesis. Journal of Mammary Gland Biology and Neoplasia. 9: 39-53. PMID 15082917 DOI: 10.1023/B:Jomg.0000023587.40966.F6 |
0.469 |
|
| 2003 |
Lamb J, Ramaswamy S, Ford HL, Contreras B, Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR, Ewen ME. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 114: 323-34. PMID 12914697 DOI: 10.1016/S0092-8674(03)00570-1 |
0.385 |
|
| 2001 |
Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HL, Biswas DK, Pardee AB, Amati B, Jacks T, Richardson A, Dyson N, Sicinski P. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proceedings of the National Academy of Sciences of the United States of America. 98: 13138-43. PMID 11687642 DOI: 10.1073/Pnas.231487798 |
0.349 |
|
| 2000 |
Ford HL, Landesman-Bollag E, Dacwag CS, Stukenberg PT, Pardee AB, Seldin DC. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. The Journal of Biological Chemistry. 275: 22245-54. PMID 10801845 DOI: 10.1074/Jbc.M002446200 |
0.455 |
|
| 2000 |
Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Research. 60: 749-55. PMID 10676663 |
0.399 |
|
| 2000 |
Pardee A, Guan R, Ford H, Fournier M, Martin K, Sager R. Blood assays for earlier detection of cancers Breast Cancer Research. 2: 1-2. DOI: 10.1186/Bcr191 |
0.333 |
|
| 1999 |
Ford HL, Pardee AB. Cancer and the cell cycle. Journal of Cellular Biochemistry. 166-72. PMID 10629116 DOI: 10.1002/(Sici)1097-4644(1999)75:32+<166::Aid-Jcb20>3.0.Co;2-J |
0.333 |
|
| 1998 |
Ford HL. Homeobox genes: A link between development, cell cycle, and cancer? Cell Biology International. 22: 397-400. PMID 10328847 DOI: 10.1006/Cbir.1998.0329 |
0.424 |
|
| 1998 |
Ford HL, Kabingu EN, Bump EA, Mutter GL, Pardee AB. Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. 95: 12608-13. PMID 9770533 DOI: 10.1073/Pnas.95.21.12608 |
0.503 |
|
| 1998 |
Guan R, Zhang J, Martin K, Ford H, Fu Y, Pardee A. Down-regulation of a homocysteine-induced novel gene in metastatic human colon cancer Gastroenterology. 114: A604. DOI: 10.1016/S0016-5085(98)82464-5 |
0.448 |
|
| 1997 |
Ford HL, Silver DL, Kachar B, Sellers JR, Zain SB. Effect of Mts1 on the structure and activity of nonmuscle myosin II. Biochemistry. 36: 16321-7. PMID 9405067 DOI: 10.1021/Bi971182L |
0.305 |
|
| 1995 |
Ford HL, Salim MM, Chakravarty R, Aluiddin V, Zain SB. Expression of Mts1, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line. Oncogene. 11: 2067-75. PMID 7478526 |
0.323 |
|
| 1992 |
Tulchinsky E, Ford HL, Kramerov D, Reshetnyak E, Grigorian M, Zain S, Lukanidin E. Transcriptional analysis of the mts1 gene with specific reference to 5' flanking sequences. Proceedings of the National Academy of Sciences of the United States of America. 89: 9146-50. PMID 1329089 DOI: 10.1073/Pnas.89.19.9146 |
0.38 |
|
| Show low-probability matches. |